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Acalypha wilkesiana ‘Java white’: 
Identification of some bioactive compounds by GC-MS 
and their effects on key enzymes linked to type 2 diabetes
In this study, we identified bioactive compounds from the 
ethanolic extracts of the leaves, stem bark and root bark of 
Acalypha wilkesiana through GC-MS analysis and investigated 
the effects of these extracts on some of the enzymes linked to 
type 2 diabetes. Plant parts were extracted sequentially with 
ethyl acetate, ethanol and water. GC-MS analysis revealed the 
presence of long-chain alkyl acids, esters, ketones and alco-
hols including phytol and phytol acetate along with some 
secondary metabolites such as xanthone, vitamin E and vari-
ous types of sterols including stigmasterol, campesterol and 
sitosterol. Ethanolic extracts of all the parts showed a dose-
-dependent inhibition of α-glucosidase and α-amylase acti-
vity. The extracts also demonstrated anti-lipase activity. The 
ethanolic extract of root bark showed the highest inhibition of 
enzymes compared to other extracts. The EC50 values (concen-
trations for 50 % inhibition) of α-glucosidase, α-amylase and 
lipase inhibition were 35.75 ± 1.95, 6.25 ± 1.05 and 101.33 ± 5.21 
µg mL–1, resp. The study suggests that A. wilkesiana ethanolic 
extracts have the ability to inhibit the activity of enzymes 
linked to type 2 diabetes. Further studies are needed to con-
firm the responsible bioactive compounds in this regard.
Keywords: Acalypha wilkesiana, α-glucosidase, α-amylase, 
lipase, type 2 diabetes, ethanolic extract
Diabetes has gradually become a major health concern in both developed and develop-
ing countries, while controlling hyperglycemia is one of the major challenges in the manage-
ment of this disease (1). Apart from hyperglycemia, almost 50 % of diabetic patients suffer 
from at least one or two diabetic complications such as diabetic retinopathy, cardiomyopathy, 
nephropathy, neuropathy and lower limb amputations, which are more noticeable in elderly 
patients (2). Approximately 108 million people were diagnosed with diabetes in 1980, 
which has increased to 422 million in 2014, with a projected increase to 642 million by the 
year 2030 (2).
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Diabetes is a metabolic disorder caused by deficiency of insulin secretion by the pan-
cr amstaff alan eatic beta-cells (type 1), insulin insensitivity, and partial pancreatic beta-
cell malfunction (type 2) (3). Type 2 diabetes (T2D) is the most prevalent form of diabetes 
and occurs due to the insensitivity of insulin to postprandial glucose overload which 
causes persistent hyperglycemia (4). The spread of this disease has been linked to societal 
and cultural changes in diet and lifestyle that could lead to obesity, a major risk factor for 
the rapidly rising prevalence of T2D (5). Obesity as a result of abdominal fat deposit may 
lead to sustained insulin resistance in obesity related T2D (6). Controlling hyperglycemia 
is a major challenge in the management of T2D.
A number of conventional drugs such as sulfonylureas, biguanides and α-glucosidase 
inhibitors are currently being used for the management of hyperglycemia as well as T2D. 
α-glucosidase is linked to the breakdown of disaccharides and starch into glucose while 
α-amylase breaks down long-chain carbohydrates into glucose (7). Inhibition of 
α-glucosidase and α-amylase is one of the key targets in the discovery of potential drugs 
for the treatment of T2D via reducing small intestinal glucose absorption (8). However, 
high cost and numerous side effects of these synthetic drugs have led to the exploration of 
alternative therapies in alleviating T2D (9). In addition, side effects including nausea, 
 diarrhea (commonly seen in patients on metformin), hypoglycemia, weight gain (sulfonyl-
ureas), increased risk of heart failures and bone fractures (thiazolidinediones) (10) led to 
the search for alternative therapies, particularly from medicinal plants. Medicinal plants 
have been reported to be rich in bioactive phenolics, which can be used to treat diverse 
diseases (11) including T2D. 
Acalypha wilkesiana ‘Java white’ is a member of the spurge family (Euphorbiaceae). It is a 
tropical and subtropical evergreen shrub with greenish yellow to white dotted green leaves 
mottled with irregular green spots. It grows in various parts of Africa but is native to South 
Pacific islands. In western Nigeria, a boiled decoction of the leaves of A. wilkesiana Müll. Arg. 
is used in the treatment of fungal infections seen in newborns, and also against hyperten-
sion and diabetes mellitus in adults (12). The leaves of this plant also possess anti-inflamma-
tory, anti-microbial and anti-pyretic activities (13). Although some hypoglycemic, anti-dia-
betic and hypolipidemic effects of A. wilkesiana Müll. Arg. of leaves and roots have been 
reported in some recent studies (12, 14, 15), the underlying mechanisms behind these effects 
and phytochemical constituents of different parts of this plant are not fully understood. 
Odoh et al. (14) and Olukunle et al. (12) reported the antidiabetic and hypoglycemic as 
well as hypolipidemic activities of root and leaf extracts, respectively, in alloxan-induced 
diabetic rats; however, stembark was not used in their studies and Odoh et al. (14) only 
qualitatively determined the phytochemical constituents in root extracts. Furthermore, 
Igwe et al. (16) only analyzed the leaf ethanolic extract to identify its bioactive compounds 
by using GC-MS while other parts of the plant were not analyzed. On the other hand, al-
though aqueous and ethanolic extracts of the leaves and root bark of this plant have been 
shown to reduce blood glucose levels in alloxan-induced diabetic animals (12, 14), the 
mechanisms behind these effects are still unknown. 
Hence, this study was designed not only to analyze the phytochemical constituents of 
the ethanolic extracts of leaf, root bark and stem bark of A. wilkesiana “Java white” via GC-
MS analysis but also to examine the effects of various extracts from the different parts of 
the plant on the activity of enzymes linked to T2D, such as α-glucosidase, α-amylase and 
lipase, to understand the mechanisms behind their reported hypoglycemic and antidia-
betic effects (12, 14).
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Absolute ethanol, dinitrosalicylic acid (DNS), ethyl acetate, n-hexane and starch were 
purchased from Merck (Germany). Acarbose, ethylenediaminetetraacetic acid (EDTA), 
morpholinepropanesulphonic acid (MOPS), orlistat (tetrahydrolipstatin), porcine pancre-
atic amylase, p-nitrophenyl butyrate (pNPB), p-nitrophenyl-α-d-glucopyranoside (pNPG) 
and yeast α-glucosidase were obtained from Sigma-Aldrich (Germany).
A Büchi Rotavapor II (Büchi, Switzerland) and a Synergy HTX Multi-mode Reader 
(BioTek Instruments Inc, USA) were used.
Plant materials
Leaves, stem bark and root bark of A. wilkesiana ‘Java white’ were collected from Ibadan, 
Nigeria, during October 2015. These plant parts were then washed and air-dried to constant 
mass, then blended to fine powder using a miller and stored in air-tight containers.
Extraction of crude extracts
One hundred grams of powdered plant sample from each plant part were initially 
defatted with n-hexane, then extracted in a sequential manner with ethyl acetate, ethanol 
and water by soaking in 200 mL of the relevant solvent for 48 h. After filtering through a 
Whatman filter paper No. 1, the extracts were concentrated in vacuo using a rotary evapo-
rator. Aqueous extracts were concentrated to dryness by placing them in a water bath set 
at a temperature of 50 °C until completely dried.
Gas chromatography-mass spectroscopic (GC-MS) analysis
Ethanolic extracts of the leaves, stem bark and root bark of A. wilkesiana were sub-
jected to GC-MS analysis. GC-MS analysis was carried out on an Agilent Technologies 6890 
Series GC coupled with an Agilent 5973 mass selective detector equipped with Agilent 
Chemstation software (Agilent, USA). A HP-5MS capillary column was used (30 m × 0.25 
mm ID, 0.25 µm film thickness, 5 % phenylmethylsiloxane). Helium was used as the car-
rier gas at a flow rate of 1.0 mL min–1 and linear velocity of 37 cm s–1. Injector temperature 
was set at 250 °C. Oven temperature was programmed to reach 280 °C from the initial 60 
°C at a rate of 10 °C min–1. One-µL injections were made in the split mode with a split ratio 
of 20:1. The MS was operated in the electron ionization mode at 70 eV and electron multi-
plier voltage of 1859 V. The operating parameters for the instrument were: ion source temp. 
230 °C, quadrupole temp. 150 °C, solvent delay 4 min and scan range 50–70 amu. Com-
pounds were identified using the NIST library by direct comparison of the mass spectral 
data of known compounds.
Inhibitory activity of plant extracts 
α-glucosidase. – α-glucosidase inhibitory activity was measured according to a pub-
lished method (17) with slight modifications. Briefly, 500 µL of 1.0 U mL–1 of the 
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α-glucosidase enzyme dissolved in phosphate buffer (100 mmol L–1, pH 6.8) was incubated 
for 20 min at 37 °C with 250 µL of extract or acarbose (standard). p-nitrophenyl-α-d- 
 -glucopyranoside (pNPG) solution (of 5 mmol L–1, 250 µL) prepared in the same phosphate 
buffer was then added to the reaction mixture and incubated for another 30 min at 37 °C. 
This caused a release of p-nitrophenol, whose absorbance was subsequently recorded at 
405 nm. The inhibitory activity was recorded as the proportion of the control lacking in-
hibitor. The experiment was performed three times.
α-amylase. – α-amylase inhibitory activity was determined by a previously published 
method (18) with slight modifications. Briefly, 250 µL (1 mg mL–1 stock) of the extracts at 
different concentrations (50–250 µg mL–1) or acarbose was incubated for 20 min at 37 °C 
with 500 µL of the enzyme (porcine pancreatic amylase 2 U mL–1) in phosphate buffer (100 
mmol L–1, pH 6.8). Then, 250 µL of 1 % starch prepared in the same buffer was added to the 
premixed solution and incubated further for 1 h at 37 °C. One mL of the color reagent, 
 dinitrosalicylate (DNS), was subsequently added and the mixture was boiled for 10 min. 
The absorbance was taken at 540 nm and the activity of inhibition was recorded as the 
proportion of the control without extract. All experiments were carried out in triplicate.
Pancreatic lipase. – The pancreatic lipase inhibitory activity was determined by a previ-
ously reported method (19). The enzyme containing buffer was prepared by adding a solu-
tion of porcine pancreatic lipase (2.5 mg mL–1) in 10 mmol L–1 MOPS and 1 mmol L–1 EDTA, 
pH 6.8. Tris buffer (100 mmol L–1 Tris-HCl and 5 mmol L–1 CaCl2, pH 7.0; 169 µL) was added 
to 100 µL of extract (50–250 µg mL–1), or orlistat; then 20 µL of enzyme buffer was added 
and incubated for 15 min at 37 °C. Afterwards, 5 µL of substrate solution (10 mmol L–1 
pNPB in dimethyl formamide) was added and incubated for 30 min at 37 °C. The lipase 
activity was subsequently determined by measuring the breakdown of pNPB to p-nitro-
phenol at 405 nm. All assays were carried out in triplicate.
Statistical analysis
Data are presented as mean ± SD. Data were analyzed using a statistical software 
package (SPSS for Windows, version 23, IBM Corporation, USA) using Tukey’s-HSD mul-
tiple range post-hoc test. Values were considered significantly different at p < 0.05.
RESULTS AND DISCUSSION
GC-MS analysis
Ethanolic extracts of the leaves, stem bark and root bark of A. wilkesiana ‘Java white’ 
were subjected to GC-MS analysis to identify some major bioactive compounds.
According to the data presented (Figs. 1, 2, 3 and Tables I, II and III), 25 phytochemi-
cals were identified from this plant, which included four major classes of compounds: 
fatty acids and fatty acid esters, phytols, xanthones and sterols, many of which have been 
reported to have various medicinal effects including α-amylase and α-glucosidase inhibi-
tory activities (20–26). In addition, EC50, or the minimum concentration required for 50 % 
inhibition of enzyme activity, was also calculated for different extracts from each part of 
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the plant for different enzymes, as presented in Table IV. However, it should be kept in 
mind that due to the difference in the nature of samples, namely, extracts (as mixtures of 
various compounds) and standards (pure compounds), their inhibitory values cannot be 
directly compared. 
Although Odoh et al. (14) determined qualitatively the presence of alkaloids, terpenoids, 
flavonoids, saponins, steroids and tannins in the root methanolic extract and Igwe et al. (16) 
identified 12 compounds in the leaf ethanolic extract, in our study, 25 major bioactive com-
pounds were identified in ethanolic extracts of various parts of the plant (Figs. 1–3 and Ta-
Fig. 1. Long-chain alkyl acids, esters, ketones and alcohols identified from the ethanolic extracts of 
 A. wilkesiana leaves, stem bark and root bark.
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bles I–III). Igwe et al. (16) identified predominantly terpenes, followed by long-chain fatty 
acids, long-chain fatty acyl alcohols, esters and their derivatives, whereas we additionally 
identified phytol, phytol acetate, vitamin E and various types of sterols such as campesterol, 
stigmasterol and sitosterol (Table I, Figs. 1–3). Apart from the leaf, the ethanolic extracts of 
root bark and stem bark were also analyzed by GC-MS in our study although no additional 
types of compounds were identified (Figs. 1–3 and Tables II and III) except xanthone and an 
aromatic amine in the ethanolic extract of root bark (Fig. 2 and Table III).
Fig. 2. Aromatics, sterols and triterpenes identified in the ethanolic extracts of A. wilkesiana leaves, 
stem and root bark.
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Fig. 3. continued..







Phytol acetate C22H42O2 338.57 16.42 5.76
6-Octadecenoic acid methyl ester C19H36O2 296.49 19.00 0.57
Phytol C20H40O 296.53 19.10 2.00
Octadecanoic acid C18H36O2 284.48 19.55 2.56
9-(4-Methoxyphenyl)xanthene C20H16O2 288.39 22.39 2.89
2-Hydroxy-1-(hydroxymethyl)ethyl 
hexadecanoate
C19H38O4 330.50 22.52 1.76
Acridin-9-yl-(4-methoxy-phenyl)-amine C20H16N2O 300.35 24.33 0.38
Oleana-11,13(18)-diene C30H48 408.70 27.22 1.48
Vitamin E (α-tocopherol) C29H50O2 430.71 27.37 1.16
Campesterol C28H48O 400.68 28.64 1.77
Stigmasterol C29H48O 412.69 28.96 2.32
Sitosterol C29H50O 414.71 29.77 1.81
The compounds listed in the table matched the same compounds in the NIST library.
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Tetradecanoic acid C14H28O2 228.37 15.56 0.39
1-Methylethyl tetradecanoate C17H34O2 270.45 16.25 0.31
Phytol acetate C22H42O2 338.57 16.41 2.00
Ethyl hexadecanoate C18H36O2 284.48 17.97 2.60
Methyl cis-13-octadecenoate C19H36O2 296.43 18.99 0.43
Phytol C20H40O 296.53 19.10 1.05
9-(4-Methoxyphenyl)xanthene C20H16O2 288.34 22.39 5.01
Stigmast-4-ene-3-one C29H48O 412.69 23.24 1.82
Campesterol C28H48O 400.68 28.64 3.08
Stigmasterol C29H48O 412.69 28.96 1.56
Sitosterol C29H50O 414.71 29.75 7.57
The compounds listed in the table matched the same compounds in the NIST library. 







4-(4-Hydroxy-3-methoxyphenyl)-2-butanone C11H14O3 194.23 14.37 0.63
Phytol acetate C23H46O 338.57 16.41 0.46
6,10,14-Trimethyl-2-pentadecanone C18H36O 268.48 16.46 0.89
Xanthone C13H8O2 196.20 16.95 1.68
Hexadecanoic acid methyl ester C17H34O2 270.45 17.30 0.43
Hexadecanoic acid ethyl ester C18H36O2 284.48 17.97 1.54
8-Octadecenoic acid methyl ester C19H36O2 296.49 18.99 1.91
(Z,Z)-9,12-octadecadienoic acid C18H32O2 280.45 19.28 0.70
9-(4-Methoxyphenyl)xanthene C20H16O2 288.34 22.38 21.02
Acridin-9-yl-(4-methoxy-phenyl)-amine C20H16N2O 300.35 24.55 0.36
Campesterol C28H48O 400.68 28.64 3.71
Stigmasterol C29H48O 412.69 28.96 2.08
Sitosterol C29H50O 414.71 29.75 9.60
The compounds listed in the table matched the same compounds in the NIST library. 
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α-glucosidase and α-amylase inhibitory activity
The effects of various extracts on the two key enzymes, α-glucosidase and α-amylase, 
implicated in T2D are shown in Figs. 4a-f. All the extracts showed significant α-glucosidase 
(p < 0.05) inhibitory activity, in a dose dependent manner. The ethanolic extracts from stem 
bark and root bark, however, showed significantly (p < 0.05) higher activities than the others. 
This is also evident from their lower EC50 values compared to other extracts (Table IV). The 
ethanolic extract of root bark showed the presence of xanthone (Fig. 2, Table III). Xanthones 
are biologically active plant phenols that have lately received profound interest (23). 
Xanthones have been studied to possess, among others, anti-inflammatory, anti-cancer, 
Fig. 4. α-glucosidase and α-amylase inhibitory activities of leaves (a and b), stem bark (c and d) and 
root bark (e and f) extracts of A. wilkesiana. Data are presented as mean ± SD of triplicate determina-
tions. a-c Different letters over the bars for a given concentration are significantly different from each 
other (p < 0.05). EtAc – ethyl acetate, EtOH – ethanol.
a)                                                                              b)
c)                                                                              d)
e)                                                                              f)
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anti-hyperglycemic and anti-hypertensive effects (24, 25). A study conducted in 2014 showed 
that xanthones extracted from the plant Swertia mussotii exerted α-glucosidase inhibitory 
activity (26). In a previous study, it was also reported that long-chain unsaturated fatty 
acids had significant α-glucosidase inhibitory activity (27). This implies that the α-glucosidase 
inhibitory activity of A. wilkesiana, especially the low EC50 values of the ethanolic root bark 
(Table IV), could be attributed to the xanthones and long-chain unsaturated fatty acids and 
their derivatives. 
In vitro pancreatic α-amylase activity was also inhibited by all extracts of plant parts, 
with the most significant (p < 0.05) activity exhibited by the ethanolic extract of root bark, 
with the lowest EC50 value of 6.25 ± 1.05 µg mL–1.
Ethanolic extracts of the various parts of A. wilkesiana have been reported to contain 
various long-chain fatty acids and fatty acid esters, e.g., tetradecanoic acid, octadecanoic 
acid, octadecanoic acid methyl ester, phytol, phytol acetate, xanthone and various sterols 
including stigmasterol (Figs. 1, 2 and 3). In a number of recent studies, plant extracts con-
taining these compounds have been shown to have α-amylase, α-glucosidase and lipase 






Ethyl acetate 74.63 ± 2.87b 296.18 ± 37.18f 384.55 ± 23.84e
Ethanol 67.18 ± 7.65b 75.35 ± 8.25c 149.70 ± 8.34c
Aqueous 88.35 ± 15.37c 118.9 ± 19.3d,e 203.71 ± 1.82d
Stem bark
Ethyl acetate 242.99 ± 41.83e 274.55 ± 31.09f 146.88 ± 19.84c
Ethanol 37.10 ± 2.71a >1000g 113.38 ± 18.23b
Aqueous 267.94 ± 24.90e >1000g 894.61 ± 36.28f
Root bark
Ethyl acetate 124.04 ± 16.72d 98.65 ± 15.11d >1000f
Ethanol 35.75 ± 1.95a 6.25 ± 1.05a 101.33 ± 5.21b
Aqueous 127.25 ± 23.60d 151.04 ± 12.59e >1000e
Standard
Acarbose 36.27 ± 1.84 53.77 ± 3.95 ND
Orlistat ND ND 0.03
Data are presented as mean ± SD values of triplicate determinations.
a-g Different superscripts in a column for a given parameter denote significant difference from each other; p < 0.05.
EC50 – the minimum extract concentration required for 50 % inhibition, ND – not determined.
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Fig. 5. Anti-lipase activity of: a) leaves, b) stem bark and c) root bark extracts of A. wilkesiana. 
Data are presented as mean ± SD of triplicate determinations.
a-d Different letters over the bars for a given concentration are significantly different from each other 
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inhibitory activity (28–30). Hence, the enzyme inhibitory activity of this plant might be 
linked to some of these bioactive compounds.
We are inclined to believe that the inhibition of these enzymes by A. wilkesiana might 
indicate potential anti-hyperglycemic efficacy, which could corroborate its folkloric use as 
a medicinal plant for the treatment and management of T2D.
Pancreatic lipase inhibitory activity
Results given in Figs. 5a-c show the inhibitory potential of the extracts of all parts for 
pancreatic lipase activity, thus demonstrating potential anti-obesogenic activity, with the 
best activity exhibited by the ethanolic extract of root bark (EC50 = 101.33 ± 5.21 µg mL–1).
Overweightness and obesity are responsible for causing insulin resistance, one of the 
two major ways of pathogenesis of T2D (31). On the other hand, the most popular screen-
ing method in the discovery of anti-obesogenic drugs is to identify potent lipase inhibitors 
(32). Hence, one of our objectives was to examine the ability of plant extracts to inhibit li-
pase. Ethanolic and aqueous extracts of the leaves have been reported to show serum tri-
glyceride lowering abilities (33). This might be due to their reducing small intestinal ab-
sorption of dietary lipids via inhibiting lipase activity. The pancreatic lipase inhibitory 
activity displayed by the ethanolic extract of root bark (Fig. 5c) with considerably low EC50 
values (Table IV) could further support the potential of A. wilkesiana for the management 
of T2D and its associated risk factors such as overweight and obesity.
CONCLUSIONS
The presence of potentially bioactive compounds in A. wilkesiana exerting carbohy-
drates and lipids digesting enzymes inhibitory effects is suggested in this study. These 
results indicate that no part of A. wilkesiana is a waste since it could contain potent inhibi-
tory activity against some key enzymes linked to diabetes and obesity, which also gives 
antecedence to its use in folk medicine. These findings specifically point out the ethanolic 
extract of stem bark and root bark as more active extracts compared to leaf extracts. Al-
though a number of bioactive compounds have been identified in A. wilkesiana extracts by 
GC-MS analysis, some additional techniques such as LC-MS or HPLC-PDA could expand 
the list of bioactive compounds, so further studies are warranted in this regard.
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